GSK's COPD Triple Combo Wins EU Nod

Ahead of a regulatory verdict in the US, GSK's triple combination therapy for COPD, Trelegy Ellipta, has won a positive recommendation in Europe.

Windmills
GSK's triple combination COPD therapy whirls through CHMP • Source: Shutterstock

GlaxoSmithKline PLC and partner Innoviva Inc. have won a positive recommendation in Europe for the approval of Trelegy Ellipta, a triple combination therapy for adult patients with moderate to severe chronic obstructive pulmonary disease (COPD).

[Sidebar#SC099472]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip